CA3231257A1 - Compound, salt of compound, antibody modification reagent, method for producing modified antibody, and modified antibody - Google Patents

Compound, salt of compound, antibody modification reagent, method for producing modified antibody, and modified antibody Download PDF

Info

Publication number
CA3231257A1
CA3231257A1 CA3231257A CA3231257A CA3231257A1 CA 3231257 A1 CA3231257 A1 CA 3231257A1 CA 3231257 A CA3231257 A CA 3231257A CA 3231257 A CA3231257 A CA 3231257A CA 3231257 A1 CA3231257 A1 CA 3231257A1
Authority
CA
Canada
Prior art keywords
igg
compound
group
salt
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3231257A
Other languages
English (en)
French (fr)
Inventor
Yuji Ito
Taku YOSHIYA
Shugo TSUDA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PEPTIDE INSTITUTE Inc
Kagoshima University NUC
Original Assignee
PEPTIDE INSTITUTE Inc
Kagoshima University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PEPTIDE INSTITUTE Inc, Kagoshima University NUC filed Critical PEPTIDE INSTITUTE Inc
Publication of CA3231257A1 publication Critical patent/CA3231257A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/88—Carboxylic acid amides having nitrogen atoms of carboxamide groups bound to an acyclic carbon atom and to a carbon atom of a six-membered aromatic ring wherein at least one ortho-hydrogen atom has been replaced
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
CA3231257A 2021-09-08 2022-09-08 Compound, salt of compound, antibody modification reagent, method for producing modified antibody, and modified antibody Pending CA3231257A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021146504 2021-09-08
JP2021-146504 2021-09-08
PCT/JP2022/033713 WO2023038082A1 (ja) 2021-09-08 2022-09-08 化合物、化合物の塩、抗体修飾試薬、修飾抗体の製造方法及び修飾抗体

Publications (1)

Publication Number Publication Date
CA3231257A1 true CA3231257A1 (en) 2023-03-16

Family

ID=85506405

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3231257A Pending CA3231257A1 (en) 2021-09-08 2022-09-08 Compound, salt of compound, antibody modification reagent, method for producing modified antibody, and modified antibody

Country Status (9)

Country Link
US (1) US20250304617A1 (https=)
EP (1) EP4400509A1 (https=)
JP (1) JPWO2023038082A1 (https=)
KR (1) KR20240052833A (https=)
CN (1) CN117916251A (https=)
AU (1) AU2022342928A1 (https=)
CA (1) CA3231257A1 (https=)
TW (1) TW202328163A (https=)
WO (1) WO2023038082A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026058917A1 (ja) * 2024-09-10 2026-03-19 味の素株式会社 抗体親和性物質を含む化合物、修飾抗体およびそれらの塩ならびに抗体誘導体または抗体－機能性物質コンジュゲートの製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008054030A1 (fr) 2006-11-02 2008-05-08 Kagoshima University Peptide liant l'igg
JP5994068B2 (ja) 2011-08-24 2016-09-21 国立大学法人 鹿児島大学 ＩｇＧ結合性ペプチド及びそれによるＩｇＧの検出および精製方法
ES3058443T3 (es) 2015-05-20 2026-03-10 Univ Kagoshima Modificación específica de anticuerpo con péptido de unión a IgG
DK3470418T3 (da) 2016-06-13 2024-09-30 Univ Kagoshima Site-specifik radioisotop-mærket antistof ved brug af using iggbindende peptid
AU2018259856B2 (en) 2017-04-28 2025-05-01 Ajinomoto Co., Inc. Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
JP7291395B2 (ja) 2017-06-16 2023-06-15 国立大学法人 鹿児島大学 ＩｇＧ結合ペプチド、及び該ペプチドによる抗体の特異的修飾
TWI886164B (zh) * 2019-10-24 2025-06-11 國立大學法人鹿兒島大學 1價ccap生成物之製造方法
JP7461180B2 (ja) 2020-03-16 2024-04-03 五洋建設株式会社 プレキャスト部材の鉄筋挿入孔の形成方法、プレキャスト部材の接合方法およびプレキャスト部材の製造方法

Also Published As

Publication number Publication date
EP4400509A1 (en) 2024-07-17
US20250304617A1 (en) 2025-10-02
AU2022342928A1 (en) 2024-03-28
JPWO2023038082A1 (https=) 2023-03-16
WO2023038082A1 (ja) 2023-03-16
CN117916251A (zh) 2024-04-19
TW202328163A (zh) 2023-07-16
KR20240052833A (ko) 2024-04-23

Similar Documents

Publication Publication Date Title
US11472865B2 (en) IgG-binding peptide, and specific modification of antibody with said peptide
ES3058443T3 (es) Modificación específica de anticuerpo con péptido de unión a IgG
KR102511249B1 (ko) 신규한 안정한 항체-약물 복합체, 이의 제조방법 및 이의 용도
RU2771292C2 (ru) Конъюгаты анти-cd71 активируемое антитело-лекарственное средство и способы их применения
JP6585600B2 (ja) Ｃ末端軽鎖ポリペプチド伸長を含有する抗体、ならびにその複合体及びその使用方法
CA2822693C (en) Radiolabled her2 binding peptides
JP2021059563A (ja) アントラサイクリン誘導体を含む、結合タンパク質薬物複合体（Ｂｉｎｄｉｎｇ ｐｒｏｔｅｉｎ ｄｒｕｇ ｃｏｎｊｕｇａｔｅｓ）
CN102665768B (zh) 肽清除剂
AU2011277999A1 (en) Multifunctional Antibody Conjugates
AU2458701A (en) Methods and compositions for prolonging elimination half-times of bioactive compounds
JP2017512464A (ja) インスリン様成長因子１受容体特異的抗体及びそれらの使用
US20180028682A1 (en) Maytansine-drug conjugates of her-2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation
CA3231257A1 (en) Compound, salt of compound, antibody modification reagent, method for producing modified antibody, and modified antibody
JP2026509871A (ja) 抗ｌｉｖ－１抗体及び抗ｌｉｖ－１抗体薬物複合体並びにその薬物的使用
JP7782851B2 (ja) ペプチド架橋剤及び当該架橋剤で架橋された架橋ペプチド
HK40109611A (zh) 化合物、化合物的盐、抗体修饰试剂、修饰抗体的制造方法及修饰抗体
US20260021213A1 (en) Method for producing fc-containing molecule modifying reagent
US12296020B2 (en) Compound comprising Fc-binding unit, and conjugate prepared using same
EA051199B1 (ru) Сшивающий агент для пептида и сшитый пептид, который сшивают с использованием указанного сшивающего агента
EP4605013A1 (en) Novel antibody drug conjugates with novel napi2b antibodies, therapeutic methods and uses thereof
HK40119528A (zh) 抗叶酸受体α抗体及使用方法
KR20230132640A (ko) 티올 반응성 에디티브를 이용한 항체-약물 컨쥬게이트의 제조 수율을 높이는 방법

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250808

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250808